Astellas Pharma, Inc. ALPMY announced that its infectious disease drug, Cresemba has gained FDA approval for the treatment of adults, who are suffering from invasive aspergillosis and invasive ...
Astellas Pharma has received the Food and Drug Administration’s permission for Cresemba (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis and invasive ...
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the ...
Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA ® (isavuconazonium sulfate), the prodrug for isavuconazole ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
NORTHBROOK, Ill., July 30, 2015 /PRNewswire/ -- Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, ...
HealthDay News — The FDA has approved Cresemba (isavuconazonium sulfate) to treat invasive aspergillosis and invasive mucormycosis, according to a press release. These rare but serious fungal ...
The CRESEMBA New Drug Application (NDA) was submitted by Astellas on July 8, 2014. CRESEMBA is being co-developed with Basilea Pharmaceutica International Ltd. Basilea submitted a European Marketing ...
Isavuconazonium sulfate 372mg; lyophilized pwd for IV inj after reconstitution; preservative-free. Isavuconazonium sulfate is the prodrug of isavuconazole. Isavuconazole inhibits the synthesis of ...
Astellas announced the launch of Cresemba (isavuconazonium sulfate) for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients. Cresemba is an azole antifungal that ...
The US Food and Drug Administration (FDA) has approved isavuconazonium sulfate (Cresemba, Astellas Pharma US), a new antifungal for the treatment of adults with invasive aspergillosis and invasive ...
NORTHBROOK, Ill., March 6, 2015 /PRNewswire/ -- Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results